Sign up to save your podcasts
Or
Share Medicare Benchmarking, Novo's Transition, and Biohaven's Setback — This Week in Biotech #52
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Medicare Benchmarking, Novo's Transition, and Biohaven's Setback — This Week in Biotech #52
In this week’s episode, we break down three major biotech stories from May 9–16, 2025:
• The White House revives the “Most Favored Nation” drug pricing model, aiming to tie Medicare prices to those paid abroad, but with little enforcement or funding, it’s more signal than substance.
• Novo Nordisk strikes a $2.2B deal to develop oral obesity drugs with Septerna, then sees the surprise resignation of its longtime CEO amid competitive pressure from Eli Lilly.
• Biohaven’s stock tumbles 22% after the FDA delays its review of troriluzole, a rare disease therapy, citing the need for an advisory committee meeting.
Subscribe for weekly biotech recaps plus deep-dive interviews with industry and academic experts.
View all episodes
By Katerina RoznikIn this week’s episode, we break down three major biotech stories from May 9–16, 2025:
• The White House revives the “Most Favored Nation” drug pricing model, aiming to tie Medicare prices to those paid abroad, but with little enforcement or funding, it’s more signal than substance.
• Novo Nordisk strikes a $2.2B deal to develop oral obesity drugs with Septerna, then sees the surprise resignation of its longtime CEO amid competitive pressure from Eli Lilly.
• Biohaven’s stock tumbles 22% after the FDA delays its review of troriluzole, a rare disease therapy, citing the need for an advisory committee meeting.
Subscribe for weekly biotech recaps plus deep-dive interviews with industry and academic experts.